Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.9204
-0.0283 (-2.98%)
At close: Jun 9, 2026, 4:00 PM EDT
0.9400
+0.0196 (2.13%)
After-hours: Jun 9, 2026, 7:37 PM EDT
Rein Therapeutics Employees
Rein Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$5,020,800
Market Cap
85.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Inovio Pharmaceuticals | 112 |
| MindWalk Holdings | 102 |
| PolyPid | 75 |
| ImmuCell | 73 |
| Rani Therapeutics Holdings | 71 |
| Biomea Fusion | 41 |
| Outlook Therapeutics | 17 |
| Rallybio | 14 |
RNTX News
- 1 day ago - Rein Therapeutics Proxy statement: Proxy filing - Filings
- 1 day ago - Rein Therapeutics Proxy statement: Proxy filing - Filings
- 8 days ago - Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright - TheFly
- 12 days ago - Rein Therapeutics Proxy statement: Proxy filing - Filings
- 22 days ago - Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 25 days ago - Rein Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Rein Therapeutics provides update on RENEW clinical trial - TheFly